This content from the 2020 ASCRS Virtual Annual Meeting is only available to ASCRS members. To log in, click the teal "Login" button in the upper right-hand corner of this page.
In late 2018, the FDA approved the toric implantable collamer lens (toric ICL, STAAR surgical). This new ICL platform offers patients another refractive surgical option for patients with myopic astigmatism. This clinical study aimed to evaluate the clinical outcomes of 120 Visian Toric ICLs implanted at Parkhurst Nuvision in San Antonio, TX.
This retrospective study evaluated 120 eyes of 62 patients with spherical equivalents of -8.11 ± 2.59 (mean +/- SD) and astigmatism of -2.40 ± 1.06 who underwent toric ICL implantation. Mean sphere, cylinder, spherical equivalent (SE) refraction, uncorrected visual acuity (UCVA), and best-corrected visual acuity (BCVA) were measured preoperatively and at the 1 day and 1-month visit.
At day one, 93% of eyes achieved a visual acuity of 20/40 or better and 75% of eyes achieved a visual acuity of 20/25 or better. At 1 month, 86.7% of eyes achieved an UCVA of 20/25 or better and 1.6% of eyes had an UCVA that was 20/40 or worse. At the 1-month post-operative visit, the average spherical equivalent was -0.25 ± 0.58 (mean +/- SD) and the average residual astigmatism was -0.76 ± 0.51. Two eyes needed an enhancement with laser vision correction, 3 eyes needed to have their ICL rotated, and 1 eye needed to have their ICL replaced for a larger size. No vision-threatening complications occurred during the post-operative period.
This retrospective analysis of 1-month outcomes suggests that the Visian Toric ICL implantation in patients with myopic astigmatism provides a safe surgical procedure with excellent refractive and visual outcomes. Further studies are needed to evaluate the long-term results.